AtriCure (NASDAQ:ATRC) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of AtriCure, Inc. (NASDAQ:ATRC) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $35.03 and traded as high as $41.54. AtriCure shares last traded at $40.54, with a volume of 210,949 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ATRC shares. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Thursday, October 30th. JPMorgan Chase & Co. upped their price target on shares of AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group boosted their price objective on AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $52.44.

AtriCure Price Performance

The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average price is $36.68 and its 200 day moving average price is $35.07. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of -66.53 and a beta of 1.47.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.10. The firm had revenue of $134.27 million for the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative return on equity of 2.54% and a negative net margin of 5.55%.The company’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Equities research analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Insider Activity

In other AtriCure news, insider Justin J. Noznesky sold 5,166 shares of AtriCure stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total transaction of $192,640.14. Following the sale, the insider owned 78,798 shares in the company, valued at $2,938,377.42. The trade was a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Sven Wehrwein sold 4,967 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total transaction of $188,746.00. Following the completion of the sale, the director directly owned 34,374 shares in the company, valued at $1,306,212. This trade represents a 12.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 18,166 shares of company stock worth $676,378. Company insiders own 3.50% of the company’s stock.

Institutional Trading of AtriCure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marks Group Wealth Management Inc boosted its stake in shares of AtriCure by 36.8% in the 2nd quarter. Marks Group Wealth Management Inc now owns 28,973 shares of the medical device company’s stock valued at $949,000 after purchasing an additional 7,788 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of AtriCure by 2,690.0% during the 1st quarter. Acadian Asset Management LLC now owns 195,582 shares of the medical device company’s stock worth $6,304,000 after purchasing an additional 188,572 shares in the last quarter. First Bank & Trust bought a new position in AtriCure during the 2nd quarter valued at about $273,000. Osterweis Capital Management Inc. bought a new position in AtriCure during the 1st quarter valued at about $9,536,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in AtriCure in the second quarter valued at about $284,000. Institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.